For the quarter ending 2025-11-30.
| Income Statement | 2025-11-30 | 2025-05-31 | 2024-11-30 | |
|---|---|---|---|---|
| Revenues | 0 | 0 | - | |
| Research and development expense | - | 0 | - | |
| General and administrative expenses | 64,002 | 40,380 | 36,837 | |
| Total operating expenses | 64,002 | 40,380 | 36,837 | |
| Loss from operations | -64,002 | -40,380 | -36,837 | |
| Financial (loss) income | -49,717 | -19,347 | 2,485 | |
| Capital gain (loss) | - | 0 | - | |
| Net loss | -113,719 | -59,727 | -34,352 | |
| Loss from available for sale assets | 0 | 0 | - | |
| Total comprehensive loss | -113,719 | -59,727 | -34,352 | |
| Earnings per share, basic | 0 | 0 | -0.001 | |
| Earnings per share, diluted | 0 | 0 | -0.001 | |
| Weighted average number of shares outstanding, basic | 732,857,211 | 42,597,394 | 31,111,352 | |
| Weighted average number of shares outstanding, diluted | 732,857,211 | 42,597,394 | 31,111,352 | |
CNBX Pharmaceuticals Inc. (CNBX)
CNBX Pharmaceuticals Inc. (CNBX)